India just got its first billion-dollar neurotechnology fund. ADI Neuroscience, announced on 28 August 2026, targets US$1 billion of investment into India’s neurotechnology sector over five years. The fund is backed by SPEC Finance India and led operationally by SPEC Finance Group CEO Karan Dinesh Singh Rawat, who said the capital will “advance neurotechnology R&D in India, create competitive products, and develop the industry domestically.” The story was first reported by RT India and syndicated through Big News Network and India Gazette.
Fund structure and scale
The US$1 billion figure is a stated five-year investment target, not committed or deployed capital and not a first-close disclosure. Portfolio construction, check size, stage focus, first-close date, and SEBI Alternative Investment Fund registration status have not been disclosed in the announcement. Named LPs beyond SPEC Finance India have not been disclosed. Named first investments have not been disclosed.
The fund is Indian, capitalised through SPEC Finance India, with operational leadership under Rawat at SPEC Finance Group. The scientific dimension of the fund is Russian: Neiry founder Alexander Panov is named as scientific adviser, and Mikhail Lebedev of Moscow State University sits on the scientific board.
Alexander Panov and the scientific side
Panov founded Neiry in 2017 in Moscow. Neiry’s consumer product is Mind Tracker, a portable EEG headband and companion app that translates EEG signals into fatigue, concentration, and stress metrics. Neiry raised roughly 541 million rubles (~US$7.4 million) in a Series A in May 2021 backed by the National Technology Initiative Support fund. Panov is described in the announcement as scientific adviser to ADI Neuroscience, not fund manager. His CEO title remains at Neiry.
Mikhail Lebedev is a Moscow State University professor and a brain-to-brain-interface researcher. Additional scientific board members have not been named.
India’s neurotech base rate before ADI Neuroscience
India has approximately 12 BCI startups, against roughly 23 in China and 101 in the United States. Cumulative Indian BCI startup funding over the past decade is approximately US$8.5 million, against roughly US$3.03 billion in the United States and US$117 million in China. A US$1 billion five-year target would exceed the entire prior decade of Indian BCI funding by roughly two orders of magnitude.
Named Indian BCI operators InsideBCI has flagged in prior coverage include Motorica India, whose COO Kavinder Beniwal was quoted in the May 2026 The Week India cover story alongside Noland Arbaugh, Phil Kennedy, and José del R. Millán. Sputnik Brain, a Bengaluru-based deeptech BCI startup, has appeared in earlier InsideBCI Google Alerts digests. NexStem is a third India-domiciled BCI operator referenced in secondary neurotech-industry coverage. Andhra Pradesh’s BRAIN programme under the Ratan Tata Innovation Hub was announced separately in August 2026 as a state-level India neurotech initiative.
Where ADI Neuroscience puts India on the global neurotech-capital map
India has been the smallest of the four large geographic neurotech-capital layers. US private capital dominates volume, with the Ackman Oxman Institute’s US$400 million commitment on 19-20 August 2026, Elon Musk’s direct ownership of Neuralink, the Bezos family’s US$100 million commitment to Allen Institute Brain Health in June 2026, and multiple US venture rounds. China’s state-industrial builder posture drives its own volume through Weiling Medical’s RMB 100 million-plus round in August 2026, MIIT’s 15th Five-Year Plan naming BCIs as a future industry on 26 August 2026, and Gestala’s separately reported ultrasound-BCI round. NATO’s DIANA network gained a Turkish neurotechnology test centre through NOROM on 23 August 2026.
If ADI Neuroscience deploys anywhere near the stated target over five years, India moves from a distant fourth on this map to a named participant. A US$1 billion India-focused neurotech vehicle changes the base-rate assumption that Indian neurotech is a research and outsourcing layer rather than a capital-formation layer.
The Russia-India scientific corridor
The Russian scientific spine on the ADI Neuroscience scientific side sits inside a broader Russia-India cross-border corridor that has strengthened across defence, energy, and technology during the past several years. Panov’s Neiry runs in Moscow. Lebedev’s Moscow State University position is a Russian academic base. The fund’s capital is Indian, and the deployment target is Indian. Whether the Russia-India scientific-and-capital arrangement carries any sanctions or regulatory-posture considerations for future US or European co-investors, or for portfolio companies with US or European customers, is not addressed in the announcement.
Not disclosed
The exact fund vehicle name, domicile, and SEBI Alternative Investment Fund registration status have not been disclosed. LP composition beyond SPEC Finance India has not been disclosed. Portfolio construction, check size, stage focus, and named first investments have not been disclosed. First-close and deployment timeline have not been disclosed. Whether Panov relocates to India for the advisory role has not been disclosed. Any sanctions or regulatory-posture assessment on the Russia-scientific / India-capital corridor has not been disclosed. Tier 1 Indian outlets (Economic Times, Mint, Business Standard) have not yet independently confirmed the announcement.
What to watch
Tier 1 Indian press confirmation. Economic Times, Mint, or Business Standard picking up the ADI Neuroscience story with independent verification of SPEC Finance India, the fund vehicle, and LP composition would move the story from announcement to established.
SEBI filing or AIF registration disclosure. A regulatory filing confirming the fund vehicle is registered and operational, rather than announced, is the next hard signal.
First named investment. A specific Indian neurotech startup receiving ADI Neuroscience capital, with amount and stage disclosed, would be the first operational read.
Whether other India-focused neurotech vehicles emerge in the coming quarters. A single fund is an announcement. A category of India-domiciled neurotech funds appearing in the next 12 months would confirm India as a fourth serious neurotech-capital layer alongside the US, China, and the alliance-adjacent European and NATO-DIANA infrastructure.